Names that move as a basket.

Busted-platform turnaround re-rated ~190% off the $2.33 low on ABCL635 Phase 1 success + Q1 beat (+98% YoY) + PT hikes (Cantor $11). The Q3 2026 ABCL635 Phase 2 VMS topline is the binary but it's a quarter out, and the tape just spiked to…

Defining binary resolved 2026-05-27: APG777/zumilokibart Part B hit (mid-dose 65.9% EASI-75, all doses p<0.001) and a record $1.3B Blackstone non-dilutive deal landed yet shares sold the news (~$95→$83) on a non-monotonic dose curve (mid >…

Phase 3 prostate-cancer win is now fully public Lancet Oncology print (2026-06-02), AUA extended follow-up (HR 0.70, 39% PCa-specific DFS gain) and the tape barely moved. The April accelerating leg (Cantor OW, EVERSANA, $4→$9) has matured…

Blood-safety turnaround now analyst-confirmed: Q1'26 (4/30) hit adj-EBITDA +$4.0M and +$6.2M operating cash on +24% product rev, drawing a BTIG Buy/$4 PT plus France EFS and BCA supply deals. But the 2.7x off the $1.15 low is largely spent…

Late-April FDA catalyst (NDA rolling review + National Priority Voucher for COMP360 in TRD) has faded into dead tape; theme stepped ACCELERATING→MATURING and volume is back to ~1x ADV. No dated catalyst in 30d the real binary is the…

3x re-rate off $1.85 to $5.77 is the $100M Apotex asset-sale (announced 2026-04-22; $75M cash upfront + $25M earnout) vs $87M cap public and priced. The 2026-06-24 shareholder vote is the only dated binary, but the board recommends FOR, so…

Only 2026 binary already fired against momentum: RESTORE-FA topline (2026-05-18) gapped +14% then closed -28.88% at $10.22 as n=16 open-label 4-week data underwhelmed the run toward $17. Now drifting low-$10s ($10.65, 2026-06-05) with no…

Binary resolved bullish: Q1 2026 (printed 5/14) beat EPS $0.14 vs $0.09, revenue $24.3M vs $22.3M, FY26 guide raised to >$120M; HCW Buy, PT $57 (5/15); IMPAVIDO license added 5/19. The rollup beat-and-raise is now confirmed in the numbers,…

Post-spike DR5-agonist biotech bleeding in a catalyst vacuum: $155→$87 (-44%), sold its own HNSCC beat, now grinding toward the $78 floor. Chondrosarcoma BLA confirmed submitted; FDA filing-acceptance decision (~late June, soft) is the…

Binary fired 2026-06-01 JADE101 Phase 1 beat (~70% IgA, q12w dosing, clean safety), PTs jumped (BTIG $74) but the tape sold the news and the company printed a dilutive $150M raise at $15.00 (2026-06-04). Catalyst spent; next own readout is…

Near-closed $27.00/share all-cash Chiesi takeout: all antitrust/FDI gates cleared (HSR 5/28, Germany 5/27, Italy 5/29); only the majority-tender condition remains, expiring 2026-06-10. Stock pinned ~$26.66, ~1.3% to deal vs ~40% break…

In-vivo CAR-T re-rate but EHA full dataset 6/11-14 is a binary INSIDE 3 trading days; topline already leaked, durability risk both ways.

Medtronic diabetes spinoff repricing as a pure-play automated-insulin-delivery / CGM story; the Abbott dual glucose-ketone exclusive sensor deal (2026-06-03) extends the ecosystem moat. But the Q4 print and the deal both fired the same day…

Feb-2026 REZOLVE-AD (atopic dermatitis) maintenance pop to $109 has fully round-tripped: NKTR is ~$57, ~38% below the $92 April secondary, -32.6% on the month with no near-term binary. The AD IL-2 Treg narrative ran ACCELERATING then…

TTFields single-asset name marked up into a binary: +24.5% over 3mo to ~$16, recovering toward the $19.25 high ahead of the Phase 3 TRIDENT GBM overall-survival readout (topline Q2 2026, ~June 30). coin-flip the edge is buying a confirmed…

Phase 2a binary already fired positive (2026-04-27: 63.5% PASI 100, 83% PASI 90 — bimekizumab-class clearance from a twice-yearly IL-23). The accelerating leg is now spent: stock topped $91, sits ~$60 and bleeding into a June 2026 lock-up…

Fertility-benefits re-rate now MATURING (mis-themed as biotech) analyst cluster done, avg PT on spot, 8-week catalyst vacuum to the 7/30 print pullback-to-$24, not a chase.

Biotech ACCEL (first coverage Canaccord $32 + insider ATM buying) but the de-risking data is 2027, no 30-day binary, ~$18M/qtr burn momentum probe, not a fat pitch.

MRD/liquid-biopsy narrative still ACCELERATING on 4 Medicare wins + best-in-class ASCO data, but the catalysts already fired and price just FAILED a breakout 2026-06-05 printed a fresh 52w high $12.53, then reversed to close $10.75 (-11%).…

FDA-regime-change relief rally into binary catalysts: Makary's 2026-05-12 ouster plus the acting commissioner's 2026-06-04 pledge against political interference in rare-disease reviews revived hope of an accelerated path for AMT-130…

AAN follow-up (2026-04-21) confirmed RAP-219 durability 90% median seizure reduction wks 9-12, 22-day half-life validating the platform, but the stock sold the news ~9% and now sits in a ~5-month data gap until bipolar-mania Phase 2…

Post-Phase-3-failure CNS microcap in a dead readout zone; the 2026-05-28 vote lifting authorized shares 150M→200M arms an ATM with no dated Sepranolone or RELIGHT topline to offset it. The 2026-06-03 pre-market pop was a low-float blip on…

Reverse-merger special situation, not a momentum trade. The 2026-06-01 Avenzo oncology merger + $215M PIPE pop already fired and has faded back toward the mid-$14s by 2026-06-07. Legacy holders keep a cash distribution + CVR + a ~2.8%…

Biotech ACCELERATING leader: upLIFT 6/8 interim + 4-house upgrade cluster, 5 rules incl vol 1.53x binary name, LOW event-risk probe.

Oral-GPCR platform story accelerating: Novo Nordisk obesity deal funds 5 targets, SEP-631 printed positive CSU Phase 1, and SEP-479 hits the ENDO 2026 stage this week. But it's a 3x into all-time highs (~$32) and the ENDO slot is…

April narrative-momentum breakout fully round-tripped: denifanstat's retail spike faded and SGMT sits at $6.76 (2026-06-05), barely above its $6.00 April offering price after the float nearly doubled to 61.75M shares. Dermatology pivot +…

Pre-binary retail run-up: SLS ran ~5x off the $1.39 low into an imminent, event-driven Phase 3 REGAL overall-survival readout (78/80 death events as of May 11, 2026). A coin-flip near 52-week highs ($8.23) with parabolic RSI lottery gamma…

Single-asset ivonescimab story where the leg that powered the ASCO run has resolved mixed: the global HARMONi-3 squamous PFS interim missed (Apr 30, −25%), then positive China-only HARMONi-6 OS (HR 0.66) sold the news (Jun 1, −6%).…

Equity re-minted around STRO-004, a DAR-8 Tissue Factor ADC, after lead luvelta was shelved. Analyst cluster (Wedbush $60, Barclays OW $56) frames a mid-2026 Phase 1 readout, but the stock has rolled over from ~$41 to ~$26 momentum fading…

GLP-1 muscle-preservation narrative got Novo's stamp (2026-06-02 free-Wegovy supply deal + first-negotiation right), spiking VERU +167% intraday on 06-04 to a +88% close. But it's a no-cash supply deal, and a June 2026 S-3 just registered…

AI-chip ACCELERATING but (rank 34%), parabolic ATH chase, ARK persistent distribution dossier wants the ~$420 shelf retest.

AI-chip theme but momentum LAGGARD (rank 88%), NVDA ARM-PC structural x86 threat + 108x P/E contested thesis, weakest cluster name.

AI-memory thesis intact but price leg cracked (+200% over 200DMA, CEO sold $36M, Burry SOXX short) into FQ3 ~6/25 binary most-saturated memory leg, correlated dup.

AI-chip cluster still ACCELERATING, but QCOM's own leg is MATURING/late: a late-May breakout to the ~$248–250 52-week-high zone failed on sub-1x volume and reverted toward the published invalidation level with retail-saturation flags and…

AI-connectivity ACCEL but mid-correction knife after -11.4% Broadcom de-rate, beta 3.96, ~25% above avg PT; correlated dup of MRVL/TSM.

Post-Hanwha re-rating failed: the 2026-06-05 weekly close ~$63.52 (−11.84%) broke the $68 base and gave back the entire $800M-deal pop. Edge-AI theme still accelerating sector-wide, but AMBA is being rejected on valuation modest +16.9%…

AI-advanced-packaging re-rate already played out (low-$40s → $79.23 ATH on 2026-04-27); the leg is now correcting, not accelerating. The Q1 beat (+27% rev, EPS +50% vs est) was sold -8.6%, and a -12% breakdown on 2026-06-05 inside a…

April discovery thesis fully played out: Needham Buy ($50), Q3 beat, company-confirmed AI data-center content, and a $150M JV cash unlock drove a ~3x to a $54.34 high. June 5 printed a -16% distribution day with the stock above the $30.50…

Advanced-packaging/OSAT bottleneck thesis is still accelerating fundamentally (AP rev guided >$3.5B 2026), but the tape just blew off: fresh 52-wk high $41.10 met a ~11% single-session reversal to ~$34, RSI unwound to ~48, and insiders…

WFE-recovery thesis has fired and is now mid-correction: Q1 (2026-05-04) beat at $256M revenue +15% QoQ, Q2 guided $290–310M, stock +241% YTD into a $78 high. Now unwinding hard -11.5% on 2026-06-05 through the 20- and 50-day amid director…

Binary resolved bullish: the 2026-04-23 Q1 beat plus a Q2 guide to $160-170M (vs $137M est) gapped MXL +34% and kicked off a ~+400% YTD re-rate, with AI-infra legs (Edgecore networking, Los Alamos HPC storage, 5G FWA) now materializing.…

Analog-cycle "AI beyond Nvidia" re-rate is rolling over: Broadcom's 6/4 guide reset hyperscaler capex, peers MCHP/Power Integrations fell 6–8% on 6/5, and NXPI lost its rising 20-EMA (−7.9% on the week to ~$301, ~12% off the 5/27 $339.95…

Agentic-AI demand drove an FY26 guide raise (~6%→12% net-sales growth), reaffirmed June 1 at the high end, plus Rosenblatt/Stifel PT raises to $65–66 a real narrative inflection that ran shares from $16 to an ATH $73.24 (June 2). Now a…

eFPGA/defense IP-royalty narrative accelerating ($168M funnel, four Intel 18A wins, RadPro rad-hard silicon); Russell 2000/3000 inclusion confirmed 2026-06-02, effective 2026-06-29 is the binary passive-bid catalyst but it's a low-float…

Legacy single-digit-multiple EMS re-rating into AMD's AI-server manufacturing arm via the ZT Systems deal; FQ2 detonated the frame (rev $4.01B vs $3.29B, +31.8% EPS beat) and the FY27 $16B target doubles the book. Narrative intact but the…

MEMS precision-timing picks-and-shovels: Q1 2026 (~2026-05-07) confirmed the AI-datacenter re-rate datacenter segment +158% YoY to ~67% of revenue, FY guide raised to ≥80%, EPS beat 23%. Narrative accelerated, but the stock now sits near…

AI-memory ACCELERATING but correlated dup of MU; peak retail-search, PT dispersion $1750-3250, viral DRAM ETF -20% distribution crack memory leg saturating.

AI memory/storage supercycle has gone parabolic Seagate sell-side targets ran from ~$605 to $1,150 in six weeks and the trade is now mainstream (fastest-growing ETF in history, 5/25). With the cohort's first crack showing (viral DRAM ETF…

Record Q1 (rev +87% YoY to $1.28B, AI ~70% of mix) printed 2026-04-28 then sold off ~18% the analyst-rally-into-print faded as feared. Broadcom's 2026-06-05 guide miss reset hyperscaler-capex expectations and dragged TER ~12% to ~$358,…

VECO is now a merger-arb proxy for Axcelis, not a standalone semicap: all-stock deal at 0.3575 ACLS/share, both shareholder votes approved (~Feb 2026), pending only China SAMR, close targeted 2H 2026. The 2026-06-09 NSA500 follow-on order…

Nuclear-baseload-for-AI is the crowded, mainstream leg of industrial-power-ai. Q1 beat (2026-05-11) closed -3%, Third Point fully exited, and an 11M-share secondary cleared at $281 (closed 2026-06-02). A FERC waiver (2026-06-02) pulled the…

Original anticipation thesis fully resolved bullish (Meta+AWS PPAs signed, 2026 EBITDA guide raised ~14% to $6.72-7.52B, PJM cleared at the $329 cap) but VST sold the news ~32% off the $219.81 high and the June-5 $148.76 close is failing…

Picks-and-shovels AI-datacenter power re-rating: DC Computing revenue doubled to $194.2M in Q1 (5/4) and the 6/3 ADH 800V converter launch slots AEIS into NVIDIA Rubin-era HVDC racks. Fundamentals ACCELERATING, but the tape broke down the…

Washed-out resi-solar name re-rated ~+66%/month into a short squeeze on the IQ SST AI-data-center power-electronics pivot (announced 2026-04-28). Post-parabolic (RSI 73-77, 50<200-EMA) and the 2026-06-17 FOMC dot-plot is a direct rate…

AI data-center-power parabola has broken FCEL fell ~30% in three sessions to $17.33 (Jun 5) into a binary Q2 print Monday 2026-06-08 before open. Still ~2x the $8.24 analyst PT (6 Hold/1 Sell/1 Strong Sell, 0 Buys), and the whole fuel-cell…

Industrial-power-for-AI name printed a ~30% revenue beat + raised FY26 guide (May 14), pulling a five-firm PT cluster to $51–60 then dropped a $1.34B sponsor-exit secondary at $47 (May 29) that capped the clean momentum leg. Theme…

Turbo supplier re-rated into a datacenter/industrial oil-free cooling narrative (Ingersoll Rand + Trane). But the move already happened: +210% YoY to all-time highs (~$32–34), sell-side fully caught up (BWS $42 on 2026-06-01, Stifel $36,…

Bitfarms-reborn BTC-miner→AI-datacenter pivot (rebranded 2026-04-06). Re-rate still hinges on signing the first HPC/AI lease none signed. The upsized $400M convert (priced 06-05, ~$7.41 strike) confirmed the funding gap; stock rolled from…

Data-center power-distribution pivot (busbars/power delivery into AI racks, ~$120M annualized run rate) is the re-rating story that ran MEI ~3x off its $4.88 low. But it's a loss-making, ~4x net-levered legacy auto supplier now trading…

Late-stage hydrogen-comeback + margin-turnaround squeeze already ran +475% off the $0.69 low to ~$3.57; Q1 beat printed 2026-05-11 and the tape is rolling near the $3.75 Susquehanna PT. Only forward edge is the binary 2026-06-30 Stream…

H2-2026 leasing inflection plus a data-center vertical guided +50% revenue / +70% project pipeline (Q1 call 2026-05-08), with a TOMS/PE takeover floor underneath. But the stock has gone nowhere since the 2026-05-07 beat-and-raise (~$26.47,…

AI point-of-care ultrasound narrative accelerating: Q1 2026 revenue +25% YoY ($26.5M), Butterfly Embedded chip-licensing +147%, first FDA-cleared blind-sweep AI tool, Compass AI and HomeCare commercializing through 2026. But the CBO sold…

TAVR disruptor at fresh 52w-high but on momentum not news, into a live $250M ATM seller, real binary ~2028 idiosyncratic, MATURING.

Cash-rich life-sciences-tools laggard (~$10.90/share net cash, no debt) bouncing off its $15.93 low after a May 6 impairment-and-guidance-cut gap-down. The leg here is activist/value-unlock (Politan ~10%, investor day pending), not an…

Broken growth (new patient starts -10-20% seq) bouncing into ADA on RSI 82.3 parabolic off a busted base; litigation circling event-relief, not a trend.

Post-ASMS product-cycle pop peaked ~$63 and rolling over (-6%), organic -4.4%, trades above raised consensus wait-for-a-higher-low fade.

Liquid-biopsy ACCELERATING but late re-rated +30% into the $136 consensus PT as the upgrade cluster completed; DXCM cleaner.

Defensive med-tech turnaround, MATURING character, no narrative velocity; recovery bounce toward a depressed PT cluster wrong archetype for size.

Med-device turnaround re-rating banked price above every raised PT, organic only +1.3%, idiosyncratic (no peer cluster); no edge today.

Post-COVID turnaround re-rate cooling, both catalysts public, no life-science-tools cluster confirmation, catalyst desert to ~Aug probe-only at best.

Broken legacy-diagnostics downtrend Q1 -10.5% miss + guide cut, near 52w low, below all MAs; value trap, track for a base above $9.92.

Implantable-CGM ADA-de-risked but fell INTO its catalyst (below 50-day, supply>demand), micro-cap value-trap DXCM is the cluster pick.

Real new growth leg Smith+Nephew pelvic-trauma distribution plus a raised FY guide ($230–233M) on a profit-inflecting SI-fusion base but the tape is broken: ~$15.50 sits below the 200-day, 50<200, ~29% off highs. Cheap medtech on a…

Synthetic-DNA tools maker re-rating as a 2nd-order AI-drug-discovery enabler (Complex Genes launch, $1B rev by FY2031, adj-EBITDA breakeven targeted Q4 FY26). But the move blew off and reversed: a +10% gap to an $80.50 ATH on 6/4 was…

Spatial-biology re-rate but Atera revenue is a 2027 story, Q1 -3% YoY, -7.3% outside-reversal off the high stretched, post-catalyst, idiosyncratic.

Busted-growth genomics name: the May 4 print cut FY26 guide 12% and broke reimbursement (ARR ~$3,300, ~$200 light). Price has doubled off the $32 low to ~$60, but that's a recovery bounce ahead of the binary early-August Q2 ARR print, not…

Optical ACCEL but secondary to cleaner COHR; +400% YTD parabola, $600M ATM supply ceiling, ETF/MEME-saturated, ~2.2x consensus PT. Peak-sentiment chase, no catalyst ~8wks WATCH.

AI-optical/glass picks-and-shovels narrative is fully public and still being marked up UBS PT $228 (6/5, new Street high) atop Mizuho $220, plus retail 'if-you-invested' clickbait (6/4) and the May photonics-ETF launch = late-stage…

Post-ADVA turnaround CONFIRMED on the 2026-05-04 Q1 beat non-GAAP GM 43.0%, revenue +15.5% YoY, optical +24% on hyperscaler DCI demand, non-GAAP EPS $0.14. The inflection fat-pitch already ran ~$7→$20; now MATURING and consolidating inside…

Optical DCI / WaveLogic-7 1.6T cycle is real, but the binary already fired: Q2 06-04 beat-and-raise (EPS $1.64 vs $1.46; FY26 guide lifted to $6.2-6.4B) sold off from a $620.37 pre-print close expectations sat above even the raised guide.…

Fiber-connectivity small-cap ripped ~39% on a Q2 revenue MISS (-15% YoY, swung to a loss) as retail bid the AI-fiber + BEAD story; backlog +39% QoQ and book-to-bill 1.3 are the only hard supports. The move already ran ~60% in a month and…

Q4 FY26 (2026-06-01) was a blowout revenue +157% YoY, EPS $1.16 vs $1.03, Q1 guide $465–475M above consensus yet the stock sold the news, and the entire sell-side raised PTs to $215–$300 the next morning. That is a narrative shifting from…

Legacy enterprise-networking name re-rated ~+98% in 3mo on the "Platform ONE/Agent ONE" AI-NetOps story + SaaS ARR +29% YoY. Now MATURING: spot $28.02 sits ABOVE consensus PT ~$26, two CEO insider blocks sold into the high, stock just…

May 8 binary resolved against the momentum longs: a clean fundamental beat (GM 47% vs the 42% target, revenue +18.7% YoY) wasn't enough EPS missed the run-up consensus ($3.88 vs ~$4.42) and cash fell $437M→$176M, triggering a 42% May…

Q1 print (reported 2026-05-11) resolved the binary benignly: $987.5M combined revenue, FY2026 guide reaffirmed at $3.63B rev / $1.45B adj EBITDA, net loss on $188M quarterly interest. Story shifts from pre-print coin-flip to a…

Networking-optical/photonics theme maturing toward saturated first US-listed photonics ETF (EUV) debuted 2026-05-13 with 15 of 40 holdings +100% YTD, a late-cycle retail-discovery marker. VIAV is the laggard test-and-measurement sleeve,…

Pivot to hyperscale AI-ASIC package-level burn-in validated by a record $41M follow-on order and >$92M H2 FY26 bookings, but the tape is blowoff: +400%+ YTD, ATH $113.20 on the 2026-06-02 William Blair day, catalyst now passed, insiders…

InP-substrate supplier to the AI optical-interconnect build (Q1 InP >50% of rev, record $100M backlog, Q2 guided to first profit in years). But the tape broke: -16% on 6/5 to ~$89 on a >$22M CEO insider sale, -38% off the 5/26 $143 ATH,…

WFE/China-localization ACCEL, orders +65%, but parabolic +280% 12mo cracked -9.4% on the 6/5 semicap selloff with Entity-List overhang WATCH for a $76-82 higher-low.

Edge-AI IP ACCEL but a June-5 blowoff reversal -12% off the 52w high, consensus PT at spot + JPM Neutral $30 exhaustion bar, no fresh-entry edge.

Merger-arb instrument (SWKS $32.50 + 0.96sh), upside capped at deal value, downside binary on a SAMR break the 52w-high/RSI signals are SWKS artifacts, outside the momentum edge.

Analog-components ACCEL (DC target doubled to ~$1B) but a late +2.5x continuation sitting at consensus PT SMTC is the cleaner cluster expression.

Legacy touch/display semi re-rating as edge-AI silicon: Core IoT +31% YoY (Q3, 5/7) toward FY26 >+40%/>$385M, plus a Google Research Coralboard/Coral NPU tie-up at I/O 2026. Narrative accelerating, but the easy leg ran $58→$149 and there's…

Precision-components AI re-rate already played ($25→$136), post-parabolic above ALL analyst PTs with a -8.4% distribution day, no catalyst to ~8/4 late chase.

Analog ACCELERATING tag but ZERO AI/HBM exposure (auto-cycle), post-catalyst momentum chase, broken quote prior session APH is the cleaner analog pick.

Big-box retailer back to positive comps (+2.0% Q1 FY27, 2026-05-28) and repositioning as the physical storefront for the AI-glasses/VR cycle via the Meta Lab rollout (50+ stores, June). But the easy +24% recovery off the April ~$60.50 low…

Binary Q1 catalyst is spent. The 2026-06-04 print beat (adj EPS $0.38 vs $0.31, sales +8.5% to $667M) but the stock rose only +0.64% after a +14% run-in the beat was fully priced. Brand-Portfolio re-rate is real yet Famous Footwear still…

Q1 FY27 binary fired beat-and-raise (Journeys +5%, 7th straight positive-comp quarter, FY adj-EPS guide lifted to $2.00–2.40). Live activist proxy contest (Radoff/Jumana ~8%, 4 board nominees) is the next catalyst. But the earnings event…

Post-earnings pop fully round-tripped: HELE fell ~28% from the late-April ~$33.73 spike back to $24.34 (2026-06-06), now resting on the $23-25 analyst PT cluster. Momentum structure broken, no accelerating leg, Q1 FY2027 (~early July)…

Pre-earnings short-squeeze/positioning ramp (+15.8% in May, activist + heavy short interest) into a binary 2026-06-17 Q1 print; consensus models a ~32% YoY EPS decline plus GPU and CAF compression, and two banks are Underweight at $31–37…

Deep-value, heavily-shorted department-store turnaround: Citigroup Buy/$22 (2026-06-01) plus a $190M tariff-refund cash catalyst into a 40%+ short book is squeeze fuel. Tactical squeeze trade on a declining business, MATURING narrative…

Macy's "Bold New Chapter" turnaround printed a clean Q1 beat (EPS $0.13 vs $0.03) and a twice-raised FY guide with growth across every banner, plus a fresh Berkshire stake but it ran to 3-year highs into the print, sell-side stayed…

Legacy watch maker re-rated ~+37% in a month to all-time highs ($37.73, 2026-06-08) on a 320bp gross-margin beat (Q1 FY27, ~2026-06-04). But the revenue beat was FX-aided (+8.1% reported vs +4.5% constant-currency) and management pulled FY…

Broken-tape legacy turnaround pinned at 52-wk lows (~$43, -30% YTD); the May discretionary-rebound bounce failed into a lower low and recent sell-side flow is downgrades (WF $45, GS/JPM $52), not an upgrade cluster. No momentum leg a…

Busted-IPO thrift retailer basing on a trade-down narrative: Q1 (rep. ~2026-05-06) net sales +8.9%, U.S. comps +6.4%, and a 2026-06-02 term-loan rate cut sparked a +14.9% 30-day move off lows toward $13–14 analyst targets. But it's a…

Hillary Super turnaround confirmed by a +47% earnings blowoff (Q1 adj EPS $0.60 vs $0.32, comps +13%, FY op-income guide hiked to $550–580M). But the catalyst has fired and the June-11 proxy fight resolved in management's favor narrative…

Strategic review ended with NO buyer (confirmed 2026-05-08) Clearlake/Apollo walked and a ~$250M customer (~10% of revenue) is leaving starting 2027. The deal-premium thesis that was the only reason to watch this is dead; PTs slashed to…

M&A special-sit the only live leg decayed from "on ice" (NYT, 2026-05-29) to "fizzled out" (thedesk.net, 2026-06-01) over the same station-divestiture/antitrust impasse; the $6.56 deal-spec spike has fully round-tripped to ~$4.40. No…

Recognition-phase genomics re-rate that already ran ~96% in a year; now fading from a new $177 high to ~$163 while activist director Corvex/Meister dumps ~$107M into strength and price sits ~13% above the $143.83 avg PT. MATURING with…

Lithium-recovery momentum proxy is rolling over: China carbonate spot -18.7% from the May-13 high (CNY 200,500 → 163,000 on Jun-5) as Bald Hill/Finniss restarts and record GFEX warrants signal a supply response. The Q2 realized-price…

Activist turnaround (Hestia's Wolf as CEO) has played out ~3x off the $8.95 low, pinned near the 52-wk high $17.09 (~$16.72). It's a buyback/cost-cut EPS re-rate with revenue still -3% YoY; Citizens ratchets its PT to $19 — but the…

Powersports turnaround leg ($52→$75.25 peak) has played out and is rolling over PII hit a fresh 52-wk high then fell to $66.06 (−4% on 2026-06-05), now below consensus PT $68. MATURING, special-sit catalyst spent (Indian sale closed…

Reciprocal-pivot fundamentals intact (Q1 PSI rev +29% to $109.4M, FY26 guide raised to $495–507M), but the momentum leg broke: shares round-tripped $10.81→$9.26 weekly close (2026-06-05), severing the $9.70 shelf. No hard catalyst until…

Reverse-merger special situation, not a momentum trade. The 2026-06-01 Avenzo oncology merger + $215M PIPE pop already fired and has faded back toward the mid-$14s by 2026-06-07. Legacy holders keep a cash distribution + CVR + a ~2.8%…

Merger-arb shell, not a momentum name. REAX's near-all-stock takeover (5.152 REAX/share, $60-80M cash cap) is worth ~$8.7 in stock at REAX $1.68; RMAX trades ~$9.05, near parity. Thin spread, ~35% downside on a break, no narrative leg…

Two-activist takeout arb resolved against longs: the board rejected Forager's $4.80 bid (5/4, "significantly undervalues") and closed the $372M debt-funded KUBRA deal (6/1), the defensive move Veradace feared. Stock round-tripped to…

Closed all-cash merger in its closing window, not a momentum setup: IKS Health buying TruBridge at $26.25 cash, definitive proxy filed, shareholder vote 2026-07-07. Stock pinned ~$26 = ~1% gross spread to a Q3 2026 close. The narrative leg…

H2-2026 leasing inflection plus a data-center vertical guided +50% revenue / +70% project pipeline (Q1 call 2026-05-08), with a TOMS/PE takeover floor underneath. But the stock has gone nowhere since the 2026-05-07 beat-and-raise (~$26.47,…

Activist-anchored distressed deleveraging: STARTEEPO Invest at 6.22% (3rd-largest holder, 13D/A 2026-06-01) bets Lexmark synergies + a 7x→3x leverage compression re-rate the levered equity. The 2026-06-04 pop to $3.49 has stalled near…

Record Q1 FY27 beat (6/4: rev $94.15M vs $89.85M est, adj EPS $(0.03) vs $(0.04), FY27 guide nudged to $425-441M) and the stock sold off, then sank again 6/5 as a $1.5B equity shelf was filed and the space cluster rolled over on SpaceX-IPO…

SpaceX listed on Nasdaq as SPCX on 2026-06-12 at a $135 offer (a roughly $1.77T valuation and $75B raised, the largest IPO ever to price), and opened into the $150–165 band on demand several times its book. The asset underneath is…

The SpaceX-IPO proxy bid that drove the April–May run is actively unwinding S&P killed the SpaceX index-inclusion catalyst 6/05, peers (Redwire, Momentus) down 20%+ on IPO fatigue while a $3B ATM caps every rally. Fundamentals (Q1 $200.3M,…

SpaceX-proxy closed-end fund rolling over into its own catalyst: NAV premium compressed from ~151% (May 21) to ~70% (June 5) while a $1B Jefferies ATM prints supply into the froth. The June 11–12 SpaceX IPO is the binary, but it strips out…

Space-defense mania ran parabolic into the 6/12 SpaceX IPO; FLY then gave back ~25% from its $48 May secondary to ~$36 on dilution (12M-sh offering + 11.11M resale registration) and IPO fatigue (RDW/MNTS -20%). Business is accelerating Q1…

Satellite-connectivity narrative has matured: the 2026-04-08 FCC spectrum order and the Q1 print already ran IRDM from ~$34 to a $53.83 high, and Oppenheimer's $60 PT (2026-06-03) is sell-side catching up late-stage recognition, not an…

Space-basket mania rolled over: LUNR lost the NASA LTV contract to Blue Origin (5/26), launched a $500M ATM dilution (6/4), and S&P pulled the SpaceX-index catalyst (6/5) as the whole complex bled. SATURATED→deflating theme with a fresh…

Drone-dominance policy basket leg cooling from ACCELERATING to MATURING (registry downgrade 2026-06-05). ONDS ran three legs on the Pentagon push + Trump equity-stake rumor (2026-05-28), $110M Q2 bookings (06-01) and a Navy ISR win…

SpaceX-IPO/drone retail mania that ripped RDW ~78% in a week (late May) is deflating: S&P's 2026-06-05 rejection of a SpaceX index killed the catalyst and the space complex is bleeding 20%+ days. Q1 missed and ~$350M dilution hit ~5/6 the…

Earth-observation/defense-ISR pure-play riding SpaceX-IPO space mania; +~496% YTD, parabolic, 15.6% short interest. But the $18M defense contract (2026-05-26) drew a -19.2% sell-the-news drop and price is rolling off June highs…

SpaceX-IPO proxy mania drove SIDU vertical into late May; mgmt cashed the hype with a $100M direct offering at $5.08 (2026-05-28) textbook distribution top-tick. Retail-squeeze name on $359K quarterly revenue. No fresh-entry edge; dilution…

Space-satellite theme ACCELERATING into the SpaceX-IPO proxy frenzy (UFO ETF crossed $1B AUM 2026-05-28); SPIR rides cluster beta on a clean Q1 beat + raised FY26 guide (05-13) and a rising PT ladder (Stifel $24, 06-04). But it's the…

Post-Q1 beat-and-fade mean-reverted from the mid-$130s April peak to a ~$104 post-print low; now a basing/recovery attempt on fresh dated catalysts (Vera Rubin NVL72 first-validation 6/1, BNP Paribas Outperform $192 init 6/2, enlarged NVDA…

GPU-cloud ACCELERATING, theses resolved bullish but +100%/6wks parabolic on a short-squeeze, correlated to held HUT pullback-only, not a chase.

BTC-miner-to-HPC re-rate re-accelerating: 1 GW Kentucky AI campus (2026-05-26) + six PT raises to $28–42 pushed through a Q1 revenue miss. The binary now is a named hyperscaler tenant landing vs. the 2026-06-02 NY data-center moratorium…

Neocloud storage-layer pick-and-shovel: B2 Neo white-labels object storage to GPU clouds; AI customers +76% YoY and >1/3 of Q1 bookings, FY26 guide raised to $161.5–163.5M. But the post-print run to the $10.86 high has cooled to $7.76…

Busted ETH/WhiteFiber holdco, not a momentum setup. Both prior break levels gave way on 6/5: BTBT closed $1.64 (-11.4%) and the 27M-share WYFI stake fell with WYFI's -15% to $23.27, while ETH cratered to ~$1,566. The ~36% SOTP discount…

Bitcoin-miner-to-AI/HPC pivot, but the diversification bounce just round-tripped: MARA gave back the entire $12.44→$15.29 May rally and closed ~$12.32 (2026-06-05, -11.7%) on a Q1 double-miss while BTC broke $62K. No accelerating leg…

Washed-out resi-solar name re-rated ~+66%/month into a short squeeze on the IQ SST AI-data-center power-electronics pivot (announced 2026-04-28). Post-parabolic (RSI 73-77, 50<200-EMA) and the 2026-06-17 FOMC dot-plot is a direct rate…

AI data-center-power parabola has broken FCEL fell ~30% in three sessions to $17.33 (Jun 5) into a binary Q2 print Monday 2026-06-08 before open. Still ~2x the $8.24 analyst PT (6 Hold/1 Sell/1 Strong Sell, 0 Buys), and the whole fuel-cell…

Industrial-power-for-AI name printed a ~30% revenue beat + raised FY26 guide (May 14), pulling a five-firm PT cluster to $51–60 then dropped a $1.34B sponsor-exit secondary at $47 (May 29) that capped the clean momentum leg. Theme…

Bitfarms-reborn BTC-miner→AI-datacenter pivot (rebranded 2026-04-06). Re-rate still hinges on signing the first HPC/AI lease none signed. The upsized $400M convert (priced 06-05, ~$7.41 strike) confirmed the funding gap; stock rolled from…

Data-center power-distribution pivot (busbars/power delivery into AI racks, ~$120M annualized run rate) is the re-rating story that ran MEI ~3x off its $4.88 low. But it's a loss-making, ~4x net-levered legacy auto supplier now trading…

Beaten-down IT reseller (−47% peak-to-trough to $97) bounced ~36% to $132 on a Q1 beat (net sales $5.68B vs $5.48B est, +9%) and an "AI-factory deployment" re-story. But it is a second-order AI derivative, narrative velocity is fading, and…

AI-enterprise ACCELERATING but own parabola cracked ~20% off the $475 ATH, sliced the low-$400s base; wait for a higher-low re-base, SNOW is our cluster expression.

AI-server ACCELERATING theme but own setup failed +25% record blowoff round-tripped to ~$49 gap-fill, catalyst spent to ~Sept.

AI-database ACCEL, Atlas re-accel +29%, but the +18.5% gap round-tripped to $350, only ~3% above the $340 failed-breakout line. Narrative accelerating, structure cracking; SNOW cleaner.

Cyber ACCEL but a snapback not a breakout (~16% below ATH), no catalyst to ~Aug repair leg;

AI-enterprise tag is derivative (VAR, hardware GP guided flat), +1% sales, death-cross intact while +35% above MAs above $103 PT value-trap geometry.

AI-storage sympathy-laggard to DELL, +22% gap to ATH then catalyst spent, FY27 guide only +8%, RSI high-70s cleaner leaders lead.

Margin/buyback/new-CEO rerate, not a narrative leg: Q1 FY27 (2026-05-28) revenue +1% YoY, ARR flat $496M, NRR 97% (from 104%). +14.7% pop on 25% op margin, $100M buyback, DiLullo named CEO. ~$9.25, below 200-DMA, at RBC fair-value PT $9…

AI-server faded leg into retail saturation (leveraged ETF) + risk-off; Mizuho PT $44 — below spot, scandal-beta stand aside until a $50 — reclaim.

Legacy CDN→security/AI-compute re-rating (+137% off the $69.78 low) is MATURING and rolling: AKAM fell -6.08% to $149.32 on 2026-06-05 on a buy.77), with Delivery -16% YoY and a $2.6B convert overhang. Real narrative, spent leg watch,…

Cyber re-rating (AtHoc FedRAMP recert, QNX momentum, buyback) drove a +50-65% two-week rip to a 52-week high $10.93 on WSB-fueled flow but a -9% June 5 reversal off the high, sell-side PTs ($4.40-8.50) all below spot, and a binary ~June 23…

Cyber ACCEL but beat-and-raise sold-the-news 6/5, analysts split $413-825, Jefferies cut cluster covered by held OKTA, watch for a higher-low reclaim.

Observability/cyber ACCEL, RSI reset to 59.5, but ATH $278 blow-off unwinding -16% with CEO+2 execs selling the high; DASH 6/9 swing. Mid-pullback off a parabola knife not base.

Supply-chain-security ACCEL but extended: above the $80.75 consensus PT, near 52w high, fwd P/E 88, Cramer flagged valuation, no catalyst ~8wks. WATCH for low-$80s 20-EMA / $70 shelf.

Cyber MATURING→SATURATED: +56% YTD above nearly every PT, RSI ~80, CNBC/IBD retail-late coverage, no catalyst to 8/12. WATCH for a 20-EMA pullback ~$130, not the 52w-high chase.

Cyber/legacy pivot, FY27 guide raised 8-10% but tape MATURING/range-bound, Hold consensus, -3.3% YTD, no momentum breakout. WATCH for a $27.76 — reclaim with the group.

Cyber megacap, NGS ARR +60%, but sold-the-news -5.9% off the $300 ATH, ~20 PT raises watch the $300 — reclaim.

SentinelOne busted post Q1 FY2027 stock cratered 2026-05-28 on an affirm-not-raise guide ($1.195-1.205B rev, midpoint below $1.206B est) plus 8% layoffs/$25M charge; sell-side splintered $15-$24. ~10 sessions of dead tape since, no…

Agentic-identity thesis is real and ACCELERATING, but Q1 FY27 prints 6/9 pre-market = hard binary inside 3 trading days with RSI ~74 sitting on the consensus PT defer the timing, not the story.

Cyber laggard: single-digit grower (+9.6%), busted chart below 50/200-DMA, only hook is undated take-private speculation. Value-trap / deal-headline name, not momentum WATCH.

Grid/advanced-conductor arms dealer to data-center power; backlog +40% YoY to ~$280M still accelerating, but the grid-power-transmission theme cooled to MATURING and the 2026-05-28 beat sold off on a soft Q1 margin guide ($0.17 vs $0.24…

Spectrum re-rating already paid: FCC's 2026-02-18 final rule lifting 900 MHz broadband to 10 MHz (implied $2.5–7B+ value) drove a ~3.7x run to the 52-wk high $67.19. Theme now MATURING B. Riley cut to Neutral 2026-06-04 (PT $69 ≈ spot),…

Cyclical electrical-products inflection (first net-sales growth since FY2022, Q2 reported 5/5) ran to a fresh 52w high $90.16 — then FAILED back to $80.61 (-5.1% on 6/5) as the May jobs report pushed the 30Y >5% and gutted the rate…

Galvanizing/coatings picks-and-shovels name that rode the grid-power buildout to a $151.67 ATH (2026-05-11), now ~9% off and digesting. Its "substation" leg is being divested (AVAIL switchgear → nVent, $975M), the Q4 binary already…

Grid-power MATURING, GOES story real but Q1 EPS miss, price above every PT, 13.9% short squeeze fuel WATCH a 20-EMA $12 hold.

Grid MATURING; ATH $391 reversed to $363 (failed breakout/bull-trap) on a Q1 rev miss, P/E ~52, a fund exited into the surge. WATCH for a $355 shelf hold or the ~7/28 Q2 print.

Monetization-beyond-ads leg (Business Agent Platform, $200/mo Hatch) is still young, but the live tape flipped to capex-dilution fear: a 6/5 report of a tens-of-$B equity raise to fund AI infra triggered an investor dump ("drunken…

Optimus/Robotaxi leg is contested and maturing, not accelerating. Robotaxi fleet shrank to 20 cars (6/4), Roadster demo slipped to August (6/5), and NVIDIA's open robotics platform plus Sam Altman are arming/attacking the humanoid moat.…

WWDC ~6/8 binary today; MATURING ai-mag7 theme, $4T mega-cap (±5-10% asymmetry) dilutes alpha on the book, edge +3.3pp fails rule 2. Consistent with prior deferrals wait for the print.

AWS reaccel (+28% YoY Q1, 15-qtr high) + Trainium royalty + Anthropic-IPO stake-markup wildcard is fundamentally ACCELERATING, but theme discovery decayed it to a single MATURING tag (2026-06-05) and the tape still won't confirm six weeks…

Contested legacy-CCaaS AI pivot, NOT accelerating: AI ARR +68% (~$125M) but core seat revenue only +8% and total growth decelerated to +9% (Q1, 4/30). Price rolling over $26.26 (6/1) → $23.52 (6/5, -10% in 4 days) as Salesforce Agentforce…

AI re-acceleration confirmed (Q1 +22% YoY, Cloud +63%), but the June 3 ~$85B equity raise adds dilution overhang and the June 6 market-wide AI-bubble selloff flips mag7 toward saturation. Megacap consolidating under its 50-day, no GOOG…

Clean Q3 FY2026 beat (Azure +40%, above its own 37–38% guide) met a -3% selloff on the ~$190B FY26 capex guide the AI-capex narrative flipped from 'spend to win' to margin/FCF anxiety. Price stalled on the 200-day MA (~$414), ~22% under…

Edge-AI silicon small-cap. Q1 blowout + Q2 guide-raise (2026-05-12) drove a parabolic to $85.77 ATH (May 26); June 5 -12.4% distribution day is the first crack. Catalyst already fired, now trades above analyst PTs ($70), no catalyst until…

Post-Q1 beat (~early May) drove a violent re-rate sell-side PTs jumped from a lone B. Riley $27 to Needham $60 (5/14) and Citizens $70 (5/15) and the stock went parabolic into late May (RSI low-80s). Now at peak retail attention (Benzinga…

Post-parabolic markdown: the AI-memory story behind a +300% run is breaking. Kerrisdale short (2026-05-19, $14 PT) reframed MRAM's top market as casino slot machines, not AI; price rolling ~$29 (06-04) → ~$23 (06-06) below every analyst PT…

Commercial-ramp inflection is real (Q1 record 8.4M-lb output, 5th straight sequential revenue quarter) but tiny against a ~$2.3B cap (~140x sales). The chart printed a parabolic blowoff near $17 late-May, then broke -10% to $12.52 on June…

Agentic-AI demand drove an FY26 guide raise (~6%→12% net-sales growth), reaffirmed June 1 at the high end, plus Rosenblatt/Stifel PT raises to $65–66 a real narrative inflection that ran shares from $16 to an ATH $73.24 (June 2). Now a…

AI-manufacturing marketplace narrative is fundamentally accelerating Q1 marketplace rev +40% YoY, FY guide raised, Siemens embedding + ~$50M stake but the 6/2 $225M secondary at $85 broke the parabolic structure; stock now ~$79, below…

All-cash $25.00/share take-private by American Industrial Partners (announced 2026-04-14, EV $1.272B, no financing condition) converted AVNS into a merger-arb pin. Narrative is dead; tape sits a few percent under the cash floor until a…

Closed deal, not a trade: Eli Lilly's definitive ~$6.3B-cash + up to $1.5B-CVR acquisition (announced 2026-03-31, ~40% premium) capped the orexin story at the bid. Stock pinned near the ~$40 cash value, PTs clustered $40–42, post-M&A…

Take-private kills the momentum trade: ARCHIMED $3.16/sh cash + CVR (announced 2026-05-01, close Q3-2026) pins the stock at the deal price. Last ~$3.14 = ~0.6% arb spread to cash plus a near-free CVR fixed-income-shaped, not narrative…

Signed take-private: Long Lake buys Amex GBT at $9.50/share cash (~$6.3B), close 2H 2026, 69% of holders locked via voting agreements. Stock pinned under $9.50 pure merger-arb, ~1.7% capped upside vs ~36% deal-break tail. No momentum leg;…

Near-closed $27.00/share all-cash Chiesi takeout: all antitrust/FDI gates cleared (HSR 5/28, Germany 5/27, Italy 5/29); only the majority-tender condition remains, expiring 2026-06-10. Stock pinned ~$26.66, ~1.3% to deal vs ~40% break…

Takeover binary already resolved: Sun Pharma signed a definitive $14.00/share all-cash merger (2026-04-26, $11.75B EV, 103% premium) and no Grünenthal topping bid emerged. OGN now trades as deal-pinned merger-arb ~6% spread to an…

Pending all-cash takeout, not a momentum name: Publicis $38.50/share cash deal (signed 2026-05-16) pins RAMP at $37.42 (June 5), a ~2.9% arb spread to a year-end-2026 close. Upside capped at the contract price; deal-break downside ~-21%…

VECO is now a merger-arb proxy for Axcelis, not a standalone semicap: all-stock deal at 0.3575 ACLS/share, both shareholder votes approved (~Feb 2026), pending only China SAMR, close targeted 2H 2026. The 2026-06-09 NSA500 follow-on order…

WFE-recovery thesis has fired and is now mid-correction: Q1 (2026-05-04) beat at $256M revenue +15% QoQ, Q2 guided $290–310M, stock +241% YTD into a $78 high. Now unwinding hard -11.5% on 2026-06-05 through the 20- and 50-day amid director…

Record Q1 (rev +87% YoY to $1.28B, AI ~70% of mix) printed 2026-04-28 then sold off ~18% the analyst-rally-into-print faded as feared. Broadcom's 2026-06-05 guide miss reset hyperscaler-capex expectations and dragged TER ~12% to ~$358,…

2026 WFE supercycle ($140–145B, +18–20% YoY) is the live, accelerating narrative and UCTT is the high-beta subsystem supplier with margin-recovery torque. But the stock is up ~4–5x to a $94.95 all-time high, then printed a -12.4%…

VECO is now a merger-arb proxy for Axcelis, not a standalone semicap: all-stock deal at 0.3575 ACLS/share, both shareholder votes approved (~Feb 2026), pending only China SAMR, close targeted 2H 2026. The 2026-06-09 NSA500 follow-on order…

Freight/LTL-recovery momentum nearly tripled ARCB off its $59 low to a fresh all-time-high $173 (June 12), but the name now trades ~14% above the $149 average analyst PT and just absorbed Amazon's June 10 LTL market entry (-4%). Late-cycle…

Fresh freight ACCELERATING but +75% vertical above EVERY analyst PT, RSI 76 blowoff, KNX is the cleaner cluster structure.

Early-cycle freight-rate recovery has re-rated SNDR from ~$20 to 52-week highs near $39, but the move front-runs an earnings inflection Q1 ($0.12 adj EPS, ops income -21% YoY) hasn't delivered. Sell-side PTs ($36–$39) now sit on the price…

Deep-cyclical trailer OEM at trough Q1'26 sales −20% YoY, negative gross margin, net debt > market cap. Backlog turned up to $837M (+$132M q/q) on a fragile freight recovery, but price sits near 52-week lows with no breakout a…

Drive-thru coffee unit-growth story re-accelerating on mobile order-ahead + a hot-food daypart Q1 systemwide comps +8.3% and FY26 guidance raised (2026-05-06). But the tape is parabolic into RSI ~83 and founder Boersma sold ~$92.5M into…

Casual-dining re-rate, not an ignition: North Italia (+7%) and Flower Child (+21% sales) scaling ~20% units plus a margin-expansion story drove +42% YTD to all-time highs and a 2026-06-10 JPMorgan upgrade. But ~$75 now sits through the…

Legacy-diner turnaround confirmed by the 2026-06-09 Q3 beat and raised FY26 guide ($3.27–3.30B vs $3.25B est); analyst upgrades clustering (WFC OW $50, Argus $60) into a 9-month-high tape. But the earnings binary already fired, price is…

Multi-year Chipotle compounding story is broken: fresh 52-week low 2026-06-03 + Morgan Stanley downgrade to Equal-Weight/$37 on margin and consumer-spend headwinds. JP Morgan's 2026-06-05 upgrade to Overweight (PT cut to $35) is the first…

Broken-IPO turnaround, not an accelerating story. The McDonald's national rollout the whole 2024 growth thesis was paused May 2025 after demand faded; what remains is a leveraged, dividend-suspended restructuring trading in low single…

Beaten-down arcade-restaurant turnaround: "back-to-basics" has comps climbing from ~-9% toward flat, the Street models the first positive revenue quarter (+1.7% YoY) on the 2026-06-15 AMC print, and a short book at >8 days-to-cover is…

De-rated former hyper-growth franchise compounder, off ~55% from its late-2024 ~$430 peak as 2024's +20% comps lapped into 2025 deceleration. Analyst split TD Cowen Hold $160 vs Stephens Overweight $225 (both 2026-06-04) frames the debate.…

Crypto-financials leg that ran on BTC>$80k has rolled over for GLXY specifically: a 265.1M-share registration (5/21) is a multi-week supply overhang, a $100M BitGo claim (5/21) adds legal risk, and CEO Novogratz flagged a market top…

Hyperliquid proxy with a fresh institutional narrative leg (ICE CEO "bigger than Nasdaq" 5/29; Hayes $100k bet 6/2), but the crypto tape just broke BTC/ETH/SOL all -10%+ in a week into 6/4, BTC sub-$68k. A 35.16M-share secondary overhangs…

Reverse merger closed; ASST is now Strive, a 19,000-BTC treasury proxy. The tradeable leg TD Cowen/HCW/Benchmark initiation wave plus deal front-run has fully played out. Now a ~1.3x-mNAV BTC vehicle with a fresh $2.55B ATM dilution shelf…

Broken-IPO falling knife: down ~69% from its $18 Jan-2026 IPO to ~$5.56, printing fresh all-time lows after slicing the prior $5.42 floor. Real crypto-custody franchise landing weekly enterprise deals, but EBITDA-negative, dead tape, and a…

Leveraged-Bitcoin-treasury (DAT) proxy thesis stays broken: diluted mNAV ~0.68x means XXI trades ~32% below its own 43,514-BTC NAV, so the accretive equity flywheel runs in reverse. BTC has stopped falling (~$63.5k, basing) but the stock…

Crypto-financials SATURATED (0.15), faded its own PDT good news to a weak close ~47% below ATH, CLARITY odds cut 90%→60% broken structure, no base.

Take-private special situation: Barry Diller's People Inc. Bid $48.30/share cash (~$18B) on 2026-06-01; stock gapped to within a few percent of the bid. The narrative leg already fired what's left is capped merger-arb spread (~3-5% up vs…

Busted-IPO turnaround: down from the $23.50 Sept-2025 IPO to a $5.74 low, now doubled off lows on a Q1 profitability inflection (first GAAP profit, FCF ~+90%, deleveraging to 4.0x). At ~$11.46 it has pushed above the $8.50–11 analyst PT…

Single-asset ITK-inhibitor binary RESOLVED: soquelitinib's 2026-05-14 Phase 1 atopic-dermatitis data printed clean (up to 75% EASI-75, durable off-drug remission), yet shares SOLD the news ~-28% and now sit ~$11.12 vs a $26.95 52-wk high.…

Binary resolved bullish: Q1 2026 (printed 5/14) beat EPS $0.14 vs $0.09, revenue $24.3M vs $22.3M, FY26 guide raised to >$120M; HCW Buy, PT $57 (5/15); IMPAVIDO license added 5/19. The rollup beat-and-raise is now confirmed in the numbers,…

Both binary catalysts already fired Novo Nordisk zaltenibart deal (closed 2025-12-01, $240M cash) and FDA approval of YARTEMLEA for TA-TMA (2025-12-23). Now a one-quarter-old launch ramp (Q1 net sales $9.9M) at ~$10.74, -39% off the $17.65…

De-risking binary already fired: positive CORAL Phase 2b (IPF cough, 60.2% reduction, p<0.0001, June 2025) plus JAMA publication. Funded into 2030 after the April raise, but the next clinical topline is H2 2027 a ~14-month catalyst desert.…

1.5–2.5x BTC-beta proxy mid-bear-leg, not a dip: BTC sub-$63K, −26% on the month, 11-day ETF outflow streak (−$3.45B), MSTR now selling. COIN ~$174 (6/4) sliced under the $180 Piper anchor; Baird just cut its PT to $142 (6/5). Falling…

Mastercard USDC settlement catalyst (6/03) printed and is being faded the same release added Ripple's RLUSD, commoditizing the 'only rail' thesis. Theme model flipped SATURATED (6/05) and Mizuho cut its PT to $85 the next day. A…

Flywheel reversed and now mechanically broken: with MSTR ~$125 the mNAV premium has collapsed below the level where issuance funds new BTC buys (Grayscale, 6/5), Strategy turned net seller (Saylor, 6/1), STRC is in a "death spiral"…

Pure M&A special situation: Nuvei is reportedly in advanced talks (Reuters, June 9) to buy Payoneer for ~$2.7B equity value (~$8/sh implied), and the tape already gapped +24% on the leak. At ~$6.75 the remaining merger-arb spread pays only…

Narrative still broken post-2026-05-05 Q1 (Q2 transaction-margin dollars guided to DECLINE); price stuck below 50/200-day in a death-cross. The 2026-05-29 "beaten-down bounceback" media chatter is bottom-fishing, not a momentum leg.…

Healthcare-staffing cyclical recovery, breaking out: AMN +101% YTD to 52-wk highs ~$32 as temp-nurse demand inflects (Jefferies +3.6% w/w; CCRN travel/allied +7% q/q) and EBITDA recovers. But price sits ~25% above the $25 avg analyst PT on…

Pinned cash merger-arb, not a momentum trade. Knox Lane (PE, no staffing overlap) is taking CCRN private at $13.25 cash; stock $13.18 (Jun 5 close) = ~0.5% gross spread. HSR waiting period lapses 2026-06-22 absent a second request. Upside…

Managed-care margin recovery off the 2025 ACA blowup: +137% to ~$59, now above the ~$55 consensus PT as sell-side upgrades (DB $80, BofA $74) arrive late confirmation, not a fresh leg. Q1 crushed ($3.37 vs $2.13) yet FY guide only >$3.40…

GLP-1-fear-reversal + census-recovery re-rate (+70% YTD) is already paid out: spot ~$192 sits below the $193.71 avg PT, ~5% off the ATH, tape flat 3 weeks, Berkshire trimming, no catalyst until the ~early-Aug Q2 print. MATURING toward…

Value-based oncology turnaround inflecting to first-ever profitability: Q1'26 revenue +41% YoY, Florida capitation now profitable, FY26 adj-EBITDA guide $0–9M. Tripled off $2.02; a 10% owner keeps buying (12k sh @ $4.75, Jun 5). Real,…

Q1 confirmed both legs bullish (adj EBITDA C$509M, Westinghouse C$122M, FY guide held), but price won't follow: the early-June bounce stalled at $114 and reversed -6.6% to $106.44 on 2026-06-05 a lower high rejected at the ~$115 — reclaim…

May catalyst cluster (NRC acceptance 5/20, SMCI MOU, $13M STS buy) is spent and the nuclear-powers-AI theme cooled ACCELERATING→MATURING on 6/05; price lost the ~$24 post-NRC base into the low $20s (intraday $22.76) with a live $400M ATM…

Nuclear-for-AI-power theme MATURING and in distribution. The 5/13 Q1 made OKLO a top-10 large-cap loser; the 5/26 DOE-plutonium bounce faded as CEO+COO sold ~$27M (10b5-1, surfaced 6/3, -12%), and shares broke to ~$58 by 6/5 under the…

Undated South Korea $200B-package binary (NuScale Tennessee/Uljin SMR; Doosan + Samsung C&T) is the only live leg, but the June 1–2 pop to ~$14 fully round-tripped and broke to a $10.50 close (6/5) on 45%-above-avg volume, pressing the…

Rare-earth ex-China leg drove a June 2 +12% spike to $19.75 on the first US mine-to-oxide Tb/Dy oxide, but it blew off: -13.5% June 5 to $15.03, a weekly close back under the $16 mid-May shelf. Fundamental narrative (ASM vote June 22,…

WTI crude is in a war-premium regime (~$92, Hormuz shut since March), yet W&T Offshore trades $4.11 near 52-week lows a Gulf producer that can't rally on its perfect macro because Q1 hedges booked a $24.5M derivative loss. The June 12…

Hormuz oil-shock beta is now UNWINDING, not accelerating: ACDC −10.1% on 2026-06-05 as the US President called Iran talks "progressing well," Iran signaled a Strait reopening, and Brent broke <$90 (WTI $91.40). The de-escalation headline…

Oil-geopolitical war-premium proxy on WTI, $1.1B net debt, weaker derivative structure; reverses on any ceasefire binary macro, not a clean setup.

The +214%-YTD deleveraging + GTA-ramp turnaround is fully recognized and losing its tailwind. Q1 (2026-05-05) resolved the binary bullishly record 74.8 kboepd, 9.5 LNG cargoes, debt-cut target doubled to ~20% but that print drove the run…

VECO is now a merger-arb proxy for Axcelis, not a standalone semicap: all-stock deal at 0.3575 ACLS/share, both shareholder votes approved (~Feb 2026), pending only China SAMR, close targeted 2H 2026. The 2026-06-09 NSA500 follow-on order…

Busted ETH/WhiteFiber holdco, not a momentum setup. Both prior break levels gave way on 6/5: BTBT closed $1.64 (-11.4%) and the 27M-share WYFI stake fell with WYFI's -15% to $23.27, while ETH cratered to ~$1,566. The ~36% SOTP discount…

MEMS precision-timing picks-and-shovels: Q1 2026 (~2026-05-07) confirmed the AI-datacenter re-rate datacenter segment +158% YoY to ~67% of revenue, FY guide raised to ≥80%, EPS beat 23%. Narrative accelerated, but the stock now sits near…

Argentina disinflation/credit-recovery trade; BMA is the best-capitalized domestic vehicle. But the explosive Milei-midterm leg (Oct 2025, ~3x off the low) is mature, Q1 ROE is a thin ~10%, and price sits mid-range near $91 off the $106…

Milei reform trade now in its delivery phase: SUPV is the highest-beta Argentine bank ADR on disinflation and credit normalization. Post-midterm mania (Oct 2025) has cooled to mid-range chop near $9.30, and June CPI ticking up to 4.6% is…

Gold-miner momentum has rolled over hard: AUGO is ~45% off its $110 high to ~$60 down 9.7% on 2026-06-06 alone as gold corrects from its $5,589 Jan peak to 2026 lows (~$4,420). Q1 (2026-05-06) printed record EBITDA ($244M) but AISC blew…

Q1 confirmed the turnaround Aripuanã record 13kt zinc, EBITDA +126% YoY, revenue $888M beat and the stock ran the whole leg to ~$15.75, near its 52-wk high. But the easy re-rate is spent: price now sits AT Citi's twice-raised $16 PT (still…

Coal-policy sympathy squeeze, now three days old with no follow-through: SXC sits at its 52-wk high $9.69 (~+75% off the $5.52 low), RSI ~80, after Trump's 2026-06-03 $700M coal package funding that lands on an Oakland export terminal and…

High-beta proxy on the 2026 oil supply-shock premium, and that premium is leaking: WTI ~$91 (2026-06-05, -3.1% session, -20% off peak) on US-Iran ceasefire/MOU optimism. BTE is +39% in a month, ~190% off lows, pinned near 52-wk highs as…

Geopolitical VLCC super-spike is rolling over: spot ex-AG broke below $100k/day on 2026-06-02, first sub-$100k in 19 weeks, off a $420k+ peak. CMB.TECH's Q2 (~80% fixed at ~$180k/day) is near-locked, but the rate has turned, the Q1…

The Hormuz-driven VLGC freight spike that took BLPG3 to a record ~$290/ton in mid-May has rolled over rates correcting hard into June as limited Strait traffic resumes (CNN 2026-06-02) and propane demand softens. Record Q4 ($1.90 EPS,…

Leveraged ~2x oil-beta proxy on the US–Iran/Hormuz war premium; +90% YTD to ~$100, top 3% of its 52-wk range. Q1 beat (2026-04-28) and $115–120 PT hikes already printed MATURING, mainstream, largely priced. Clean Feb–March entry (~$40–60)…

Gov-capital re-rate (2026-05-21 CHIPS $2B + equity stakes) and the 2026-05-06 Q1 blowout are already priced; price tagged $63 on 2026-05-26 then rolled, -8% on 2026-06-05. Quantinuum's 2026-06-04 IPO faded market no longer paying up for…

Government-bet leg ($100M Commerce LOI, 5/21) is digested, not fresh. Sell-side caught up triple $40 PTs on 6/2 QTUM ETF at $5B, and Quantinuum's $14.3B IPO (6/3) faded on day one (6/4), adding quantum equity supply. Theme…